Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Recurrence

Uterine Cervical Neoplasms

Disease Attributes

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Antineoplastic Agents

All Drugs and Chemicals

Niraparib

Dostarlimab

Poly(ADP-ribose) Polymerase Inhibitors

Enzyme Inhibitors

Niraparib: 200 mg, oral, once daily, days 1-21

dostarlimab: 500 mg IV, every three weeks for 4 cycles followed by 1000 mg every six weeks for up to two years

dostarlimab

Lead Gyn Onc, Nurse

Ingrid Block, APRN

Ashley Sheets

Sharon Robertson, MD

Maria Stambaugh

Tara Castellano, MD

Chrystal Axford

Linda Duska, MD

Debra Richardson, MD

The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.

Patients will have tests and exams to see if they are eligible for the clinical trial. If found eligible, the patient will receive treatment with Niraparib daily and dostarlimab by vein every three weeks for 4 cycles then every six weeks.

Patients will receive the study treatment as long as there is evidence that the tumor is not growing or spreading and they are not having any unacceptable, bad side effects.

Patients will be monitored during treatment with tests and exams and after treatment completion for up to 5 years.

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Phase II Trial of Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer (OU-SCC-STAR)

The proportion of patients treated with Niraparib and dostarlimab who achieve CR or PR, evaluated using RECIST v1.1

To determine the nature and degree of toxicity in combination of Niraparib and dostarlimab

To estimate the duration of response of patients treated with combination of Niraparib and dostarlimab

To estimate the progression free survival of patients treated with combination of Niraparib and dostarlimab

To estimate the overall survival of patients treated with combination of Niraparib and dostarlimab

Tesaro, Inc.

University of Oklahoma

Spots Global Cancer Trial Database for recurrent cervix cancer